The changing landscape in drug resistant-tuberculosis: an analysis of recent advances

References

• Keshavjee S, Farmer PE. Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med. 2012;367:931–936.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. Morb Mortal Wkly Rep. 2006;55:301–305.
   PubMedGoogle Scholar
• World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization Document. 2006; WHO/HTM/TB/2006.361:1–174.
   Google Scholar
• Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis in a rural area of South Africa. Lancet. 2006;368:1575–1580.
   PubMed Web of Science ®Google Scholar
• Monedero I, Caminero JA. MDR-/XDR-TB management: what it was, current standards and what is ahead. Expert Rev Respir Med. 2009;3:133–145.
   PubMedGoogle Scholar
• Monedero I, Caminero JA. Common errors in multidrug-resistant tuberculosis management. Expert Rev Respir Med. 2014;8:15–23.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global tuberculosis report 2014. World Health Organization Document. 2014; WHO/HTM/TB/2014.08:1–149.
   Google Scholar
• Organization WH. Global tuberculosis report. World Health Organization Document. 2015; WHO/HTM/TB/2015.22:1–192.
   Google Scholar
• Monedero I, Furin J. Programmatic management of children with drug-resistant tuberculosis: common sense and social justice. (Editorial). Public Health Action. 2015;5:92.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidance on ethics of tuberculosis prevention, care and control. World Health Organization Document. 2010; WHO/HTM/TB/2010.16:1–24.
   Google Scholar
• Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363:1005–1015.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization Document. 2014; WHO/HTM/TB/2014.11:1–403.
   Google Scholar
• Feng Y, Liu S, Wang Q, et al. Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: a meta-analysis. PLoS ONE. 2013;8(2):e55292. doi:10.1371/journal.pone.0055292.
   Google Scholar
• Walker TM, Kohl TA, Omar SV, et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis. 2015;15(10):1193–1202.
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360:2397–2405.
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371:723–732.
   PubMed Web of Science ®Google Scholar
• Ndjeka N, Conradie F, Schnippel K, et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis. 2015;19(8):979–985.
   PubMed Web of Science ®Google Scholar
• World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. World Health Organization Document. 2013; WHO/HTM/TB/2013.6:1–57.
   Google Scholar
• Harausz E, Cox H, Rich M, et al. QTc prolongation and treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2015;19:385–391.
   PubMed Web of Science ®Google Scholar
• Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014;58:2979–2981.
   PubMed Web of Science ®Google Scholar
• Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366:2151–2160.
   PubMed Web of Science ®Google Scholar
• Olaru ID, Von Groote-Bidlingmaier F, Heyckendorf J, et al. Novel drugs against tuberculosis: a clinician’s perspective. Eur Respir J. 2015;45:1119–1131.
   PubMed Web of Science ®Google Scholar
• Organization WH. The use of Delamanid in the treatment of multidrug resistant tuberculosis. Interim policy guidance. World Health Organization Document. 2014; WHO/HTM/2014.23.
   Google Scholar
• Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med. 2015;191:943–953.
   PubMed Web of Science ®Google Scholar
• Dawson R, Diacon AH, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015;385:1738–1747.
   PubMed Web of Science ®Google Scholar
• Development GAfTD. A phase 3 study assessing the safety and efficacy of bedaquiline plus PA-824 plus linezolid in subjects with drug resistant pulmonary tuberculosis. [2015; cited 2016 Jan 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT02333799.
   Google Scholar
• Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367:1508–1518.
   PubMed Web of Science ®Google Scholar
• Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J. 2015;45:161–170.
   PubMed Web of Science ®Google Scholar
• Sorgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;40:1430–1442.
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Pontali E, Migliori GB. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. (Editorial). Eur Respir J. 2015;45:25–29.
   PubMed Web of Science ®Google Scholar
• Lessem E, Cox H, Daniels C, et al. Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives. Int J Infect Dis. 2015;32:56–60.
   PubMed Web of Science ®Google Scholar
• Van Deun A, Aung KJM, Halim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182:684–692.
   PubMed Web of Science ®Google Scholar
• Hwang TJ, Dotsenko S, Jafarov A, et al. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open. 2014;4(1):e004143.
   PubMed Web of Science ®Google Scholar
• Dooley KE, Obuku EA, Durakovic N, et al. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis. 2013;207:1352–1358.
   PubMed Web of Science ®Google Scholar
• Tiberi S, D’Ambrosio L, De Lorenzo S, et al. Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. Eur Respir J. 2016;47(1):333–336.
   PubMed Web of Science ®Google Scholar
• Dhar N, Dubée V, BAllell L, et al. Rapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable β-lactam antibiotic. Antimicrob Agents Chemother. 2015;59:1308–1319.
   PubMed Web of Science ®Google Scholar
• Nunn AJ, Rusen ID, Van Deun A, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials. 2014;15:353.
   PubMed Web of Science ®Google Scholar